CClinicalTrials.gg
WithdrawnNCT06445270Updated Aug 26, 2026

Lifestyle Interventions to Improve Glycemic Parameters and Reduce Gestational Diabetes in High-risk Pregnant Individuals

An interventional study of GDM Prevention Program in Gestational Diabetes and Pregnancy Complications, sponsored by Indiana University. Withdrawn at 1 site in United States. Open to female participants aged 14 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Indiana University · Not applicable, Interventional, and Prevention

Why this study was withdrawn
No funding
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
14 Years and older
Sex
Female
01

Study summary

The goal of this study is assess the impact of a higher intensity dietary and activity counseling program to improve blood sugar control and reduce the chance of developing gestational diabetes (GDM) as compared to the current standard diet and activity counseling.

Read the detailed description

GDM is associated with adverse maternal and newborn outcomes, as well as potential lifelong consequences. Currently, clinical guidelines recommend screening for pre-existing Type 2 diabetes mellitus at new obstetric visits for individuals at high risk of developing GDM. For those who do not screen positive, but still may be at risk for GDM, standard practice is for basic diet, exercise, and weight gain counseling.

In this study, eligible participants will be randomized into one of two groups: usual care with standard diet and exercise counseling or a GDM prevention program that consists of a more intensive exercise and monitoring program.

All participants will be asked to wear an activity tracker and continuous glucose monitors (CGMs) at specified time points throughout their pregnancy. Blood will be drawn at specified time points to measure hemoglobin A1c, lipids, and HOMA-IR measures.

02

Conditions studied

  • Gestational Diabetes
  • Pregnancy Complications

Keywords

  • gestational diabetes
  • prevention
  • pregnancy
  • continuous glucose monitor
03

In context

Diabetes, Gestational

842 studies on the registry are indexed under Diabetes, Gestational; 198 are open to participants now.

Browse Diabetes, Gestational studies →

Lead sponsor

Indiana University is the lead sponsor of 958 studies on the registry; 200 are open to participants now.

Of its 142 completed or terminated interventional studies of FDA-regulated products, 112 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Gestational age less or equal to 16 + 6 weeks confirmed via ACOG dating guidelines AND one of the following
  • 35 years of age or older
  • Family history of first degree relative with diabetes mellitus
  • Body Mass Index (BMI) greater than or equal to 30
  • Hemoglobin A1c value between 5.9% to 6.4%

Exclusion criteria

Exclusion Criteria:

  • Multiple gestations
  • Current diagnosis of Type 1 or 2 diabetes mellitus including a diagnosis during this pregnancy
  • Pre-pregnancy chronic (>2 weeks) usage of systemic steroids (inhaled and short term usage acceptable)
  • Planned pregnancy termination
  • Currently taking or took 3 months prior to conception Metformin
  • Unable to provide informed consent in English or Spanish
  • Major fetal anomalies listed below that are known prior to enrollment.

Major fetal anomalies:

  • Congenital diaphragmatic hernia
  • Congenital cystic adenomatoid malformation
  • Pleural effustions
  • Chylothorax
  • Bronchogenic cyst
  • Bronchopulmonary sequestration
  • Anomalous pulmonary venous return
  • Tricuspid atresia
  • Mitral atresia
  • Double right ventricle
  • Ebstein's malformation
  • Pulmonary atresia
  • Hypoplastic left heart syndrome
  • Aortic coarctation
  • Fetal arrhythmias
  • Transposition of the great vessels
  • Tetrology of Fallot
  • Double outlet right ventricle
  • Aortic stenosis
  • Holoprosencephaly
  • Anencephaly
  • Dandy-Walker malformation or variant
  • Septo-optic dysplasia
  • Neural tube defect
  • Vein of Galen aneurysm
  • Bilateral renal agenesis
  • Cystic renal disease
  • Obstructive uropathy
  • Horseshoe kidney
  • Megacystis microcolon
  • Cloacal abnormality
  • Achondrogenesis
  • Thanatophoric dysplasia
  • Thoracic dysplasia
  • Osteogenesis imperfecta
  • Short rib polydacyly
  • Any skeletal defect with suspected small thorax
  • Hypophosphatemia
  • Any karyotypic abnormality
  • Any suspected genetic syndrome
  • Cleft lip/palate
  • Micrognathia
  • Hydrops
  • Fetal anemia (\<35% on cordocentesis)
  • Neck mass
  • Gastroschsis
  • Omphalocele
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • No intervention
    Control

    This arm consists of standard of care counseling for diet and exercise.

  • Experimental
    GDM Prevention Program

    This arm consists of a more intensive exercise and monitoring program. .

    Behavioral: GDM Prevention Program

Interventions

  • BehavioralGDM Prevention Program

    Participants will receive hybrid and group monthly contacts with registered dieticians and lifestyle coaches. Participants will attend monthly in-person physical activity sessions.

06

What researchers measure

Primary outcomes

  1. Time spent in euglycemia

    percentage of time in a day spent in euglycemia

    Time frame: 7 days per month

07

Study locations

1 site
  • Sidney and Lois Eskenazi Hospital
    Indianapolis, Indiana 46202, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06445270
Lead sponsor
Indiana University
Collaborators
Northeastern University, University of Texas
Responsible party
David Haas (Munsick Professor of Obstetrics and Gynecology, Indiana University) — Principal investigator
First posted
Jun 6, 2024
Start date
Aug 2026 (estimated)
Primary completion
Aug 2030 (estimated)
Completion
Dec 2031 (estimated)
Last update
Aug 26, 2026

Study contacts

David M Haas, MD
principal investigator · Indiana University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion